Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

2019 ARIA Care pathways for allergen immunotherapy

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Interaction between filaggrin mutations and neonatal cat exposure in atopic dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cesarean delivery and risk of atopic dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A EAACI drug allergy interest group survey on how European allergy specialists deal with β-lactam allergy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Allergiske sygdomme: Kapitel 36

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiUndervisningpeer review

  2. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. EAACI guidelines on allergen immunotherapy: Executive statement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Dynamics of plasma levels of specific IgE in chlorhexidine allergic patients with and without accidental re-exposure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • ARIA Working Group
Vis graf over relationer

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.

OriginalsprogEngelsk
TidsskriftAllergy
Vol/bind74
Udgave nummer11
Sider (fra-til)2087-2102
Antal sider16
ISSN0105-4538
DOI
StatusUdgivet - nov. 2019

Bibliografisk note

© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

ID: 58996538